000			03433cam a22005177a 4500
001			w30791
003			NBER
005			20230116102904.0
006			m o d
007			cr cnu||||||||
008			230116s2022 mau fo 000 0 eng d
040			_aMaCbNBER _beng _cMaCbNBER
100	1		_aEisenberg, Matthew D.
245	1	4	_aThe Impact of Direct-to-Consumer Advertising on Outpatient Care Utilization / _cMatthew D. Eisenberg, Brendan Rabideau, Abby E. Alpert, Rosemary J. Avery, Jeff Niederdeppe, Neeraj Sood.
260			_aCambridge, Mass. _bNational Bureau of Economic Research _c2022.
300			_a1 online resource: _billustrations (black and white);
490	1		_aNBER working paper series _vno. w30791
500			_aDecember 2022.
520	3		_aThere is much debate about the effects of pharmaceutical direct to consumer advertising (DTCA) on health care use. In this paper, we inform this debate by examining the effects of DTCA on office visits, as well as treatment courses resulting from those visits, for five common chronic conditions (hypertension, hyperlipidemia, diabetes, depression, and osteoporosis). In particular, we examine whether office visits result in use of drug therapy and/or continued office visits over time. We test these questions by combining data on pharmaceutical advertising from Nielsen with claims data from 40 large national employers, covering 18 million person-years. We analyze a non-elderly population by exploiting plausibly exogenous variation in advertising exposure across areas due to the implementation of Medicare prescription drug coverage which led to larger increases in advertising in areas with high elderly share of population compared to low elderly share areas. We find that advertising increases the number of office visits for the non-elderly for the advertised condition. We also find substantial spillovers -- a large share of the increased office visits from advertising are associated with use of non-advertised generic drugs or do not result in use of any drugs. Finally, we find that the increase in office visits due to DTCA is associated with continued engagement with a physician through multiple consecutive follow up visits over time.
530			_aHardcopy version available to institutional subscribers
538			_aSystem requirements: Adobe [Acrobat] Reader required for PDF files.
538			_aMode of access: World Wide Web.
588	0		_aPrint version record
690		7	_aGeneral _2jelc
650		7	_aGeneral _2jelc
084			_aI10 _2jelc
690		7	_aAnalysis of Health Care Markets _2jelc
650		7	_aAnalysis of Health Care Markets _2jelc
084			_aI11 _2jelc
690		7	_aHealth Behavior _2jelc
650		7	_aHealth Behavior _2jelc
084			_aI12 _2jelc
690		7	_aGovernment Policy • Regulation • Public Health _2jelc
650		7	_aGovernment Policy • Regulation • Public Health _2jelc
084			_aI18 _2jelc
700	1		_aRabideau, Brendan.
700	1		_aAlpert, Abby E.
700	1		_aAvery, Rosemary J.
700	1		_aNiederdeppe, Jeff.
700	1		_aSood, Neeraj. _921019
710	2		_aNational Bureau of Economic Research.
830		0	_aWorking Paper Series (National Bureau of Economic Research) _vno. w30791.
856	4	0	_uhttps://www.nber.org/papers/w30791
856			_yAcceso en línea al DOI _uhttp://dx.doi.org/10.3386/w30791
942			_2ddc _cW-PAPER
999			_c390496 _d349058